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Abstract
Introduction: Patients with hematologic malignancies have greater risk-factors for primary bloodstream infections (BSI).
Methods: From 2004–2009, we analyzed bacteremia caused by extended-spectrum beta-lactamase Escherichia coli (ESBL-
EC) (n=100) and we compared with bacteremia caused by cephalosporin-susceptible E. coli (n=100) in patients with
hematologic malignancies.
Objective: To assess the clinical features, risk factors, and outcome of ESBL-EC BSI in patients with hematologic
malignancies, and to study the molecular epidemiology of ESBL-EC isolates.
Results: The main diagnosis was acute leukemia in 115 patients (57.5%). Death-related E. coli infection was significantly
increased with ESBL-EC (34% vs. control group, 19%; p=0.03). Treatment for BSI was considered appropriate in 64 patients
with ESBL-EC (mean survival, 2456345 days), and in 45 control patients this was 4436613 (p=0.03). In patients not
receiving appropriate antimicrobial treatment, survival was significantly decreased in cases compared with controls
(266122 vs. 2766442; p=0.001). Fifty six of the ESBL-EC isolates were characterized by molecular analysis: 47 (84%)
expressed CTX-M-15, two (3.6%) SHV, and seven (12.5%) did not correspond to either of these two ESBL enzymes. No TLA-1
enzyme was detected.
Conclusions: Patients who had been previously hospitalized and who received cephalosporins during the previous month,
have an increased risk of ESBL-EC bacteremia. Mortality was significantly increased in patients with ESBL-EC BSI. A polyclonal
trend was detected, which reflects non-cross transmission of multiresistant E.coli isolates.
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Introduction
Bacterial resistance has increased in recent years, is related with
the use of broad-spectrum antibiotics in humans and animals, and
is at present considered a public health problem in communities’
worldwide [1]. Enterobacteriaceae is a frequently found group of
microorganisms in hospital-, health-care related, and community-
acquired infections [2].
Acquired resistance to b-lactam antibiotics is mainly mediated
by extended-spectrum beta-lactamases (ESBLs) [2]. More than
700 distinct types of beta-lactamases have been described [3]. The
increasing prevalence of ESBL producers among enterobacterial
isolates may be caused by dissemination of resistant traits,
proliferation of epidemic strains, or transfer of the resistant
gene-carrying plasmids [4]. ESBL-producing Escherichia coli (ESBL-
EC), particularly those producing CTX-M types, are emerging
pathogens worldwide [4].
Knowledge of risk factors for ESBL-EC bacteremia will
contribute to identify patients who are at higher risk, in order to
start empirical therapy in a more timely fashion with proper
coverage against these microorganisms [2]
The objective of this study was to assess the clinical features, risk
factors, and outcome of ESBL-EC bloodstream infection (BSI) in
patients with hematologic malignancies, and to study the
molecular epidemiology of ESBL-EC-carrying isolates in a non-
epidemic situation.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35780Materials and Methods
Hospital setting
The Instituto Nacional de Cancerologı ´a (INCan) is a tertiary
oncology teaching hospital in Mexico, with 150 beds. The hospital
has 7,500 hospital discharges, 3,450 surgeries per year and 30,000
chemotherapy-intravenous (IV)-infusion sessions per year.
Clinical data
We obtained ethical approval from the Instituto Nacional de
Cancerologı ´a Ethics Committee. We performed a retrospective
case-control study in patients with hematologic malignancies, with
a positive blood culture for E. coli. Cases were considered patients
with E. coli isolated from blood cultures, resistant to cephalospo-
rins, and inhibition of the resistance with clavulanic acid (ESBL-
EC). The control group included patients with a cephalosporin-
susceptible E. coli positive blood culture, taken 630 days prior to
the date of isolation of the case strain. For patients who underwent
multiple hospitalizations during the study period, the earliest E. coli
isolated from blood culture was considered the index episode. One
control patient was selected for each case. We did not obtain
informed consent because we included only the strains isolated as
part of clinical management and microbiology routine.
The following data were collected: demographic factors;
invasive procedures; hospitalizations during the previous 90 days;
days of severe neutropenia (,500 cell/mm
3); chemotherapy
treatment and medical procedures (30 days prior to the index
infection); presence of severe sepsis or septic shock and use and
type of antimicrobial agents employed during the previous month.
Bacteremia type was classified in: A) Primary bacteremia;
considered in those patients with positive blood cultures who
presented clinical sepsis, severe neutropenia (,500 cell/mm
3) and
no specific infection site. B) Secondary bacteremia; when a patient
had a specific site of infection with the same strain isolated from
the infection site and from blood cultures. C) Catheter related
bacteremia; were those patients with long-indwelling catheter and
fever or shiver after catheter use, and positive blood culture drawn
from the catheter .2 hours of positivity to peripheral positive
blood culture, taken on the same day consecutively [5].
Clinical outcome (60 days after the infectious episode) was
considered as alive, infection-attributable death, infection-non-
related death, and lost to follow-up. Health-care related infection
was considered in those patients who had .72 hours of
hospitalization or had been hospitalized during the previous 2
weeks [6].
Bacterial isolates
We included all positive blood cultures taken from January 2004
to December 2009. Blood samples were processed by the
automated blood culture BACTEC 9240 System (Becton-Dick-
inson Microbiology Systems). Appropriate antimicrobial treatment
was considered when this had been initiated within the first 48 h of
first symptoms and if the patient had received this for at least
.72 h, including an antibiotic with susceptibility for the isolated
E. coli strain.
Antimicrobial susceptibility testing and detection of ESBL
All E. coli isolates were identified by standard microbiological
procedures. Detection of antimicrobial susceptibility testing was
performed by the automated MicroScan method (Dade-Behring,
Sacramento, CA, USA). E. coli ATCC 25922 was utilized for
quality control accordingly to Clinical and Laboratory Standards
Institute (CLSI) guidelines [7].
Identification for ESBL production was performed by the
double disk synergism test following CLSI recommendations [7].
K. pneumoniae ATCC 700603 was used as positive control for ESBL
production.
Genomic DNA typing
For Pulse-field gel electrophoresis (PFGE) typing, whole cell
DNA was obtained according to the method described by
Kaufman [8,9]. DNA was digested with XbaI (Gibco, BRL, UK)
and separated in a 2% agarose gel (Pulsed Field-Certified,
Pronadisa, Madrid, Spain) with a Gene-Path System (Bio-Rad,
CHEF MAPER II, USA). Gels were stained with ethidium
bromide and analyzed according to the criteria of Tenover et al
[10], and Gel Compar II software.
Plasmid profile
Plasmids were extracted from clinical isolates by the method of
Kieser et al [11]. DNA was visualized after vertical electrophoresis
in ethidium bromide-stained 0.7% agarose gels. Plasmids R6K
(40 kb), RP4 (54 kb), R1 (205 kb), and pUA21 (300 kb) were used
as molecular size markers.
Genetic identification of ESBL
Template DNA was prepared from two fresh colonies
resuspended in 100 ml of distilled water and the cells were lysed
by heating at 95uC for 10 min. Cellular debris were removed by
centrifugation at 15,000 g for 2 min; the supernatant was diluted
1:10 in distilled water and utilized as a source of template DNA for
amplification. PCR amplification for each gene was detected using
the specific oligonucleotides: blaCTX-M, CTX-MF, 59-GCTG-
TTGTTAGGAAGTGTG-39 and CTX-MR, 59-GGTGACGAT-
TTTAGCCGCC-39; forblaSHV, those reported previously
1, and
blaTLA-1, TLA-1F, 59-TCTCAGCGCAAATCCGCG-39 and
TLA-1R, 59-CTATTTCCCATCCTTAACTA-39. PCR amplifi-
cation was carried out in a 50-ml reaction volume using a thermal
cycle 2700 instrument (Applied Biosystems). The reaction mixture
contained 5 ml of heat-extracted template DNA, 10 pmol of each
primer, 16 reaction buffer, 2 mM MgCl2, 0.2 mM of each
deoxynucleoside triphosphate, and 1.5 U of Taq DNA polymerase.
PCR was performed under the following conditions: 5 min of
denaturation at 94uC; 25 cycles of 30 sec at 94uC, 30 sec at 58uC,
and 30 sec at 72uC, and a final extension for 7 min at 72uC. In all
cases, the resulting PCR products were analyzed in 1.5% agarose
gels and samples producing one sharp band were purified with a
column kit (High Pure
TM PCR Purification Kit, Boheringer, USA)
and utilized for sequencing reactions with the dideoxy chain
termination using an automatic sequencer (ABI PRISM 377-18 kit
EL:Taq FS Dye Terminator Cycle Sequencing Fluorescence-
Based Sequencing). Primers used for the PCR amplification were
employed also for sequencing the amplified PCR products. Amino
acid sequences were obtained using the translate tool available at
ExPASy (http://www.expasy.ch/tools/dna). Multiple alignments
of nucleotide and amino acid sequences were performed with
ClustalW (http://clustalw.genome.jp/) software, and the sequenc-
es were compared with the CTX-M-15 (AY044436) and SHV-1
(AF148850) genes. New genomic data was not generated in this
study.
Statistical methods
Comparison of categorical variables and percentages between
groups was carried out by the Pearson chi-square test or the Fisher
exact test, as appropriate. Logistic regression analysis was
performed to find the association between variables. Reported
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35780Figure 1. Escherichia coli-ESBL isolated from 2004 to 2009. Total number of Escherichia coli extended-spectrum beta-lactamases (ESBL) isolated
from blood cultures at Instituto Nacional de Cancerologı ´a, Mexico City (2004–2009).
doi:10.1371/journal.pone.0035780.g001
Table 1. Demographic and clinical characteristics in patients with EC-ESBL and controls.
Characteristic Escherichia coli-ESBL (n=100) Controls (n=100) Total (n=200) P
Mean age 6 SD* (years) 38.2617 38.6617 38.4617 0.897
Female gender, n (%) 55 (55) 42 (42) 97 (49) 0.089
Primary bacteremia 88 (88) 79 (79) 167 (84) 0.226
Secondary bacteremia 10 (10) 17 (17) 27 (14)
Catheter-related bacteremia 2 (2) 4 (4) 6 (3)
Previous hospitalizations (within 3 months) 93 (93) 80 (80) 173 (87) ,0.01
Mean days hospitalization 18612 16613 17612 0.01
Mean days of CVC 74679 67674 71677 0.615
Fever and neutropenia 90 (90) 76 (76) 166 (83) 0.01
Mean days of neutropenia 16627 9612 13622 0.02
Previous chemotherapy (within 30 days) 75 (75) 78 (78) 153 (76) 0.711
Septic shock 30 (30) 18 (18) 48 (24) 0.068
*SD: Standard deviation.
doi:10.1371/journal.pone.0035780.t001
Escherichia coli ESBL Bloodstream Infection
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35780Table 2. Clinical characteristics in patients with EC-ESBL and controls.
Characteristic Escherichia coli-ESBL (n=100) Controls (n=100) Total (n=200) P
Malignant disease Leukemia 68 (68) 47 (47) 115 (58) 0.02
Lymphoma 21 (21) 38 (38) 59 (30)
Multiple myeloma 5 (5) 7 (7) 12 (6)
Myelodysplasia 6 (6) 8 (8) 14 (7)
Comorbidity Diabetes mellitus 6 (6) 8 (8) 14 (7) 0.546
HIV 3 (3) 0 (0) 3 (1.5)
Renal failure 1 81) 3 (3) 4 (2)
BMT* 5 (5) 13 (13) 18 (9)
Chemotherapy Induction 48 50 98 0.512
2
nd induction 22 19 41
3
rd or 4
th scheme 8 5 13
Palliative 12 7 19
Conditioning 5 9 14
*BMT=Bone marrow transplantation.
doi:10.1371/journal.pone.0035780.t002
Figure 2. Antimicrobials used in Escherichia coli ESBL and in the control group. Antimicrobials used during the previous month in
extended-spectrum beta-lactamase Escherichia coli and the E.coli control group.
doi:10.1371/journal.pone.0035780.g002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35780Odds ratios (ORs) with 95% confidence interval (95% CI) were
made. P values#0.05 were considered statistically significant.
Variables with a p value#0.1 in the univariate analysis were
further tested by means of logistic regression using the forward
conditional method. Comparisons of survival were analyzed by
means of the log-rank test. Kaplan-Meier curves were performed.
Multivariate analysis was performed with logistic regression
analysis; all variables statistically significant by univariate analysis
were included. The statistical analysis software employed com-
prised Epi-Info (ver. 6) and STATA (ver. 9.1).
Results
A total of 14,764 blood cultures were taken during the study
period. Of these, 2,852 (19%) were positive, 670 with E. coli (23%)
of which 205 episodes (31%) were due to ESBL-EC: 100 patients
with hemato-oncologic malignancy were included. A hundred EC-
cephalosporin susceptibility patients were included as control
group (all also with hemato-oncologic malignancy). There was
detected a progressive increase in ESBL-EC isolation from blood
cultures from 2004 (14.7%) until 2009 (65.1%) (Figure 1).
Previous hospitalization was present in 93 of ESBL-EC vs. 80 in
control (p=0.01). BSI was considered as a health-related infection
in 84 cases and in 72 controls (p=0.06). All patients were
hospitalized at the hematological ward. Eighteen patients have
been bone marrow transplantation, in 6 of them it was performed
more than 6 months before the bacteremia. The most frequent
underlying condition was diabetes mellitus (n=14, 7%). Other
demographic and clinical characteristics are shown in Table 1 and
Table 2.
Seventy four patients in the ESBL-EC group and 29 patients in
the control group had received antimicrobials during the previous
month (p,0.0001). The most frequent antibiotics used were
cefphalosporins 6 aminoglycoside (Figure 2).
All isolates remained fully susceptible to carbapenems. ESBL-
EC producers were 95.3% susceptible to amikacin, 42.9% to
gentamicin, 5.7% to ciprofloxacin, and 46.7% susceptible to
trimethoprim/sulfamethoxazole (TMP/SMX). For E. coli control
isolates, 100% were susceptible to amikacin (p=0.09), 88% to
gentamicin (p,0.0001), 60% to ciprofloxacin (p,0.0001), and
88% were susceptible to TMP/SMX (p=0.680).
Mean survival in alive patients with ESBL-EC was 3906393
days, while in the control group, this was 8126628 (p=0.009).
Treatment for E. coli BSI was considered appropriate in 64
patients with ESBL-EC (mean survival, 2456345 days) and in 45
control-group patients (mean survival 4436613 days) (p=0.03).
Also, in patients who did not receive an appropriate antimicrobial
treatment, mean survival was decreased in ESBL-EC compared
with the control group (266122 vs. 2766442; p=0.001) (Table 3).
Analyzing mean survival according to appropriate or non-
appropriate antimicrobial treatment in the ESBL-EC group was
statistically different (p=,0.001). The same analysis in the control
group showed no difference (p=0.11). The Kaplan-Meier curve is
depicted in Figure 3. There was no relationship between previous
antimicrobial use and outcome (p=0.205), neither on comparison
of time of neutropenia or mortality (p=0.154).
In the logistic regression analysis, the variables found to be
independently associated with ESBL-EC BSI were: hospitalization
during the previous 3 months (OR=3.6; 95% CI, 1.3–9.9;
p=0.01), and the use of cephalosporins during the previous month
(OR=1.8; 95% CI, 0.9–3.4; P=0.05).
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35780Molecular characterization of ESBL-EC producers
From the 100 EC-ESBL clinical isolates, 56 were randomly
selected for further molecular characterization. Macrorestriction
genomic DNA analysis showed three minor clonal groups with
.85% of similarity; group A (four isolates); group B (three
isolates), and C (two isolates); 47 of 56 (83.9%) isolates
corresponded to non-genetic-related isolates, suggesting non-cross
transmission in this hospital. A positive PCR product of the
expected size of 810 pb kb that corresponded to the bla-CTX-M
ESBL was identified in 84% (47/56). Figure 4. Concerning the
plasmids contained in ESBL-EC producers, the majority of the
isolates analyzed harbored from 1–3 different plasmids (size range,
60–275 kb).
Discussion
Over the past few years, a significant increase in the number of
ESBL-EC-associated BSI has being reported in several parts of the
world [2,3]. E. coli is the most frequent microorganism isolated
from blood cultures in our hospital; it represents 20% of all of the
isolates from BSI, and of these, 37.8% are ESBLs, although the
proportion of ESBLs isolated has increase steadily every year since
its first isolation in 2004 representing 64% of the is E coli isolates
from BSI during 2009. The incidence of ESBL-EC in other
medical centers is reported as 4–6% in Latin America (1997–
2000), 5% in the Asian Pacific and South Africa (1997–1999), 5%
in Europe (1997–1999), and 1.5–16.7% in Taiwan (2002–2006)
[12–15]. There is a trend toward increasing ESBL-EC incidence
with substitution of susceptible strains (Figure 1).
Genotyping of ESBL-EC isolates indicated in the majority of
the isolates non-relatedness, suggesting non-cross transmission; this
situation has been reported previously by other authors [12]. In
Mexico, the most frequent enterobacterial-ESBL producers
causing hospital acquired infections has been identified the
SHV-5 enzyme [15–17] and more recently, it has been substituted
by CTX-M-15 ESBL, a phenomenon described already in other
parts in the world [16–19]. In this study we detected non-genetic-
related groups among ESBL-EC-produced clinical isolates, while
the CTX-M-15 enzyme was prevalent; this situation suggests
plasmid-mediated dissemination of the bla-CTX-M-15 gene, as was
identified with the bla-SHV-5 gene. CTX-M-producing bacteria
acquire resistance to all generations of cephalosporins, while
remaining susceptible to carbapanems [20], as we could see in this
study.
>In cancer patients with prolong hospitalization and neutropenia
who had received antibiotics for prolonged time periods are factors
that enhance the opportunity for these bacteria to cause infections
[21–23]. In this institution we do not use antimicrobial prophylaxis
in neutropenic patients. We found that the previous cephalosporins
use, was statistically significantly higher in ESBL-EC harboring
patients than in controls. It is important to consider that the group
of leukemia includes more patients with ESBL-EC BSI, it must be
related with a more aggressive chemotherapy and a deeper and
longer neutropenia stage compared with control patients.
Figure 3. Kaplan Meier survival curve for Escherichia coli ESBL and control patients according to antimicrobial treatment. Kaplan-
Meier survival curve for patients with extended-spectrum beta-lactamase Escherichia coli and the E. coli control group, stratified according to
appropriate vs. non-appropriate antimicrobial treatment.
doi:10.1371/journal.pone.0035780.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35780A determining factor in the outcome of infected patients is
choosing the appropriate empirical therapy within the first 48 h of
the first symptoms and within the first 24 h of the positive blood
culture. The majority of authors have found that inadequate
antimicrobial therapy is associated with poorer outcome [24–26].
Carbapenems use has been associated with the low risk of death
in cases of serious infections caused by these pathogens [25,26]; all
of our isolates remained fully susceptible to carbapenems in vitro;
thus, these antimicrobials are first line therapy in patients
suspected of having ESBLs.
The presence of ESBL has been associated with increased
mortality, longer duration of hospitalization and increased hospital
costs [1,24–27]. Previous studies have found that malignancy is a
mortality-associated risk factor, and patient with a ESBL-EC
isolated in a blood-culture have ,4 times greater overall mortality
compared with non-ESBL-producing isolates [28,29]. Crude
mortality rates for bacteremia in neutropenic patients range from
12 to 42%; with the highest rates usually related with gram-
negative bacteria, and reached 83% among those hospitalized in
an intensive care unit [15]. In an eight year survey, the overall
mortality associated with BSI caused by E.coli in patients with
hematological malignancies was 20.9% [15]. In this study,
mortality was increased in patients with ESBL-EC BSI vs. control
patients (34 vs. 19%; p=0.03), the sole isolation of an ESBL-EC
was associated with an increase risk of death.
The results herein reported may not be applicable in settings
with a different epidemiological context; however, as control and
case patients were selected from the same hospital and same
clinical ward, the potential of selection bias should be negligible.
The prevalence of ESBL-EC gastrointestinal colonization among
patients with neutropenic cancer has been reported to be around 30%
in other Spanish hospitals in Spain [30], we have no knowledge of it in
our hospital [30,31]. It is absolutely necessary to proceed to a
monitoring of fecal-colonization in these patients and develop anti-
infective therapeutic protocols tailored to the results of this colonization.
Patients with hemato-oncological malignancies, particularly
patients with leukemia, who have been hospitalized for a long
period and who have received cephalosporins during the previous
month have a major risk of ESBL-EC bacteremia. Mortality is
increased in ESBL-EC BSI, even in patients who received
appropriate antimicrobial treatment. Multiresistant strains reflect
a polyclonal trend that is substituing susceptible isolates over time.
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